Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
SAN DIEGO, May 05, 2017 -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) (the “Company”), announced today that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options on May 4, 2017 to eight (8) new employees (the “Optionees”) exercisable for an aggregate of up to 24,500 shares of the Company's common stock (the “Option Shares”), with a per share exercise price of $0.97, which was the closing price of Cytori’s common stock on the Nasdaq Capital Market as of May 4, 2017. The stock options have a ten-year term and vest over a period of four years, with one quarter of the Option Shares vesting on the first anniversary of each Optionee’s employment commencement date with the Company, and with the remainder of the Option Shares vesting over the ensuing three years in thirty-six (36) equal, consecutive, monthly installments, in each case subject to each such Optionee’s continued employment with the Company as of the applicable vesting dates. The stock options are subject to the terms and conditions of the Company’s 2015 New Employee Incentive Plan and the stock option agreements pursuant to which the stock options have been granted.
The stock options were granted as an inducement material to the Optionees’ entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).
About Cytori Therapeutics, Inc.
Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. Cytori Nanomedicine™ is developing encapsulated therapies for regenerative medicine and oncologic indications. For more information, visit www.cytori.com.
Cytori Therapeutics, Inc. Tiago Girao 1.858.458.0900 [email protected]
